DEPLETION OF PROTEIN-BOUND FURAZOLIDONE METABOLITES CONTAINING THE 3-AMINO-2-OXAZOLIDINONE SIDE-CHAIN FROM LIVER, KIDNEY AND MUSCLE TISSUES FROM PIGS

被引：96

作者：

HOOGENBOOM, LAP

BERGHMANS, MCJ

POLMAN, THG

PARKER, R

SHAW, IC

机构：

[1] State Institute for Quality Control of Agricultural Products (RIKILT‐DLO), Wageningen, 6708 PD

[2] Central Veterinary Laboratory, Weybridge

[3] Department of Applied Biology, University of Central Lancashire, Preston

来源：

FOOD ADDITIVES AND CONTAMINANTS | 1992年 / 9卷 / 06期

关键词：

FURAZOLIDONE; NITROFURANS; BOUND RESIDUES; DEPLETION; ANALYTICAL METHOD;

D O I：

10.1080/02652039209374117

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

Ten 3-month-old pigs were treated with feed containing 300 mg furazolidone per kg for a period of 7 days, followed by withdrawal periods of 0, 1, 2, 3 or 4 weeks (two per group). The treatment resulted in the formation of protein-bound metabolites containing an intact 3-amino-2-oxazolidinone (AOZ) side-chain that could be chemically released and then detected in liver, kidney and rump muscle tissues even 4 weeks after dosing. In tissues from animals killed at the end of the medication period, 993, 600 and 124 ng of AOZ were released from 1 g of liver, kidney and muscle respectively. In the tissues of the animals killed after a further 4 weeks the corresponding levels were 41, 7 and 10 ng/g respectively. It may be concluded that long withdrawal periods prior to slaughter for human consumption are required for pigs treated with furazolidone, because of the long residence time of protein-bound AOZ and the possibility that it might be released from its protein-bound form in the stomach and subsequently be transformed into a hydrazine.

引用

页码：623 / 630

页数：8

共 9 条

[1]

Bos R.P., Neis J.M., Gemert P., Henderson P.T.H., Mutagenicity testing with the Salmonella/hepatocyte and the Salmonella/microsome assays, Mutation Research, 124, pp. 103-112, (1983)

[2]

Food And Drug A., Part V. New Animal Drugs. Furazolidone (NF-180), Federal Register, 41, pp. 19906-19921, (1976)

[3]

Hoogenboom L.A.P., Kammen M., Berghmans M.C.J., Koeman J.H., Kuiper H.A., The use of pig hepatocytes to study the nature of protein-bound metabolites of furazolidone, Food and Chemical Toxicology, 29, pp. 321-328, (1991)

[4]

Hoogenboom L.A.P., Tomassini O., Oorsprong M.B.M., Kuiper H.A., The use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone, Food and Chemical Toxicology, 29, pp. 185-191, (1991)

[5]

Innes J.R.M., Ulland B.M., Valerio M.G., Petrucelli L., Fishbein L., Hart E.R., Pallotta A.J., Bates R.R., Falk H.L., Gart J.J., Klein M., Mitchell I., Peters J., Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: A preliminary note, Journal of the National Cancer Institute, 42, pp. 1101-1114, (1969)

[6]

Neis J.M., Yap S.H., Gemert P., Roelofs H.M.J., Bos R.P., Henderson P., Activation of mutagens by hepatocytes and the 9000 g' liver supernatant from human origin in the salmonella typhimurium mutagenicity assay

[7]

comparison with rat liver preparations, Mutation Research, 164, pp. 41-51, (1986)

[8]

Stern I.V., Hollifield R.D., Wilk S., Buzard J.A., The anti-monoamine oxidase effects of furazolidone, Journal of Pharmacology and Experimental Therapeutics, 156, pp. 492-499, (1967)

[9]

Vroomen L.H.M., Berghmans M.C.J., Leeuwen P., Struijs T., Vries P.H.U., Kuiper H.A., Kinetics of 14C-furazolidone in piglets upon oral administration during 10 days and its interaction with tissue macro-molecules, Food Additives, 3, pp. 331-346, (1986)

← 1 →